The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.80

Today's change-0.17 -2.85%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.80

Today's change-0.17 -2.85%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc down (U.S.)$0.17

Infinity Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.17 or 2.85% to (U.S.)$5.80. Over the last five days, shares have lost 11.45% and are down 26.11% for the last year to date. This security has underperformed the S&P 500 by 55.06% during the last year.

Key company metrics

  • Open(U.S.) $5.92
  • Previous close(U.S.) $5.97
  • High(U.S.) $6.02
  • Low(U.S.) $5.72
  • Bid / Ask(U.S.) $4.97 / (U.S.) $6.95
  • YTD % change-26.11%
  • Volume316,245
  • Average volume (10-day)387,581
  • Average volume (1-month)635,538
  • Average volume (3-month)742,683
  • 52-week range(U.S.) $4.75 to (U.S.) $14.41
  • Beta1.45
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward12.85×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.61
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-117.70%

Although this company's net profit margin is negative, it is above the industry average and implies that Infinity Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue99154
Total other revenue--------
Total revenue99154
Gross profit--------
Total cost of revenue--------
Total operating expense48474397
Selling / general / administrative91099
Research & development39383488
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-3943-39-93
Interest income (expense), net non-operating000-1
Gain (loss) on sale of assets--------
Other--------
Income before tax-3943-38-93
Income after tax-3943-38-93
Income tax, total00----
Net income-3943-38-93
Total adjustments to net income---1----
Net income before extra. items-3943-38-93
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-3942-38-93
Inc. avail. to common incl. extra. items-3942-38-93
Diluted net income-3942-38-93
Dilution adjustment--0----
Diluted weighted average shares49504949
Diluted EPS excluding extraordinary itemsvalue per share-0.800.84-0.78-1.91
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.800.84-0.78-1.91